Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Hiram Walker who wrote (134)	4/8/1998 2:26:00 AM
From: LoLoLoLita	Read Replies (1) \| Respond to of 642

Hiram, I don't think the drug companies are going to go out of business because people switch to using plant extracts. Viagra and MUSE both retail for about $10 per dose, and you said you're already getting 10-20 calls per day on Viagra. Little VVUS sold over $100 M of MUSE hard-ons in their first year. Well, those Boomer guys calling you are probably not all impotent; many just want it bigger/harder/longer. But that's a whole 'nother story, unrelated to LLY. ----- But I have been doing some thinking about Evista, and, coming up with some reasons why there is really no hurry to jump in and buy LLY at prices higher than 60. The main thing that bothers me is related to your point about drugs being expensive, and reimbursements cut back. Well, most every insurance policy I've seen that covers prescription drugs limits coverage to treating illness, and they typically don't explicitly cover drugs or treatments for purposes of preventing illness. Preventive care is almost always limited to annual physical exams and associated blood tests and diagnostic procedures, with some policies throwing in vasectomies or other procedures that can minimize future health care costs (e.g., bearing children). So, Hiram, if Evista is approved now for preventing osteoporosis, how many women are reimbursed by insurers for this drug? And, if some users are not reimbursed now, why would this change if LLY can, in future, add breast cancer prevention and heart disease prevention to the list of FDA-approved uses? David